{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform 12-lead ECG.', 'Perform physical and ophthalmic examinations, including vital signs.', 'Measure weight.', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Administer GO-QoL questionnaire.', 'Subjects will be discharged from the study center after all of the procedures have been', 'completed.', '9.5.6.14.2 Month 12 - Follow-Up Contact for Subjects Who Relapsed in', 'Study HZNP-TEP-301', 'Subjects who complete the Week 24 Visit will be contacted 6 months later via phone or email by', 'research staff to enquire if any treatment for TED has been received since last study contact. If', 'yes, subject will be questioned regarding type of treatment and outcome/response.', '9.5.6.15 Month 18', '9.5.6.15.1 Month 18 - Follow-Up Contact for Proptosis Non-responders in', 'Study HZNP-TEP-301', 'Subjects who complete the Month 12 Visit will be contacted 6 months later via phone or email', 'by research staff to enquire if any treatment for TED has been received since last study contact.', 'If yes, subject will be questioned regarding type of treatment and outcome/response.', '9.5.6.15.2 Month 18 - Follow-Up Contact for Subjects Who Relapsed in', 'Study HZNP-TEP-301', 'Subjects who complete the Week 24 Visit will be contacted 12 months later via phone or email', 'by research staff to enquire if any treatment for TED has been received since last study contact.', 'If yes, subject will be questioned regarding type of treatment and outcome/response.', 'This is the final contact for subjects who relapsed in Study HZNP-TEP-301.', '9.5.6.16 Month 24 - Follow-Up Contact for Proptosis Non-responders in', 'Study HZNP-TEP-301', 'Subjects who complete the Month 12 Visit will be contacted 12 months later via phone or email', 'by research staff to enquire if any treatment for TED has been received since last study contact.', 'If yes, subject will be questioned regarding type of treatment and outcome/response.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 103 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'This is the final contact for proptosis non-responders in Study HZNP-TEP-301', 'The end of the trial is defined as the date of the last subject contact at Month 24.', '9.6', 'Statistical Methods and Determination of Sample Size', 'Detailed statistical analyses will be presented in a separate statistical analysis plan (SAP), and', 'analyses presented in the SAP will supersede those presented in the protocol. Some key points', 'identified for statistical analyses are outlined below.', 'The primary analyses will be conducted on the Intent-to-Treat (ITT) population. All efficacy and', 'safety endpoints will be summarized using descriptive statistics and/or number and percentage of', 'subjects, and will be stratified by the treatment received in HZNP-TEP-301 as well as overall.', '9.6.1 Enppoints', 'Study endpoints will be evaluated for all subjects from Baseline to Week 24.', '9.6.1.1 Primary Endpoint', 'The primary outcome measure is the proptosis responder rate (percentage of subjects with a', '> 2 mm reduction from Baseline in proptosis in the study eye, without deterioration 1> 2 mm', 'increase] of proptosis in the fellow eye) at Week 24.', '9.6.1.2 Secondary Enppoints', '1. Percentage of subjects with a CAS value of 0 or 1 in the study eye at Week 24.', '2. Mean change from Baseline to Week 24 in proptosis measurement in the study eye.', '3. Diplopia responder rate (percentage of subjects with baseline diplopia > 0 in study eye', 'who have a reduction of > 1 grade with no corresponding deterioration [> 1 grade', 'worsening] in the fellow eye) at Week 24.', '4. Mean change from Baseline to Week 24in the GO-QoL questionnaire overall score.', '9.6.1.3 Exploratory Enppoints', '1. The overall responder rate (percentage of subjects with > 2-point reduction in CAS AND', '> 2 mm reduction in proptosis from Baseline, provided there is no corresponding', 'deterioration [ 2 point/mm increase ] in CAS or proptosis in the fellow eye) at Week 24.', '2. The Clinical Measures of Severity individual response status frequencies and percentage', 'of responders for each component of clinical severity at Week 24.', '3. The mean change from Baseline to Week 24 in the CAS.', '4. The overall responder rate at Week 24 stratified by the level of response (high', 'responders, responders, low responders, and non-responders; see Section 9.6.3.2.1 for', 'definitions).', '5. The mean change from Baseline to Week 24 in the GO-QoL questionnaire VF and A', 'subscale scores.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 104 of 118']\n\n###\n\n", "completion": "END"}